Neurocrine Biosciences NBIX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $668.6M+39.7% | $478.6M+11.8% | $428M+22.9% | $348.3M+13.9% | $305.8M-10.4% | ||
| $26.6M+2.3% | $26M+0.8% | $25.8M+4.5% | $24.7M-0.4% | $24.8M+5.5% | ||
| $222.3M+2.0% | $217.9M-3.5% | $225.7M+5.7% | $213.5M+4.8% | $203.8M+4.2% | ||
| $118M-28.7% | $165.4M+92.5% | $85.9M+173% | -$117.3M+3.2% | -$121.2M+1.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $248.9M+92.2% | $129.5M+92.1% | $67.4M+61.2% | ||
| $148.9M-7.1% | $160.2M-0.5% | $161M+7.8% | $149.4M+153% | $59M+35.9% | ||
| —— | —— | —— | —— | -$2.6M-2,700% | ||
| —— | —— | —— | —— | —— | ||
| $3.2M-22.0% | $4.1M+5.1% | $3.9M+2.6% | $3.8M+2.7% | $3.7M+2.8% | ||
| —— | —— | -$8.6M+84.7% | -$56.1M+19.0% | -$69.3M-86.8% | ||
| —— | —— | —— | —— | —— | ||
| $863.7M+10.3% | $782.7M+22.9% | $636.8M+12.3% | $567.3M+7.1% | $529.9M-11.0% | ||
| $34.8M-4.4% | $36.4M-16.7% | $43.7M+13.2% | $38.6M+2.4% | $37.7M-1.3% | ||
| $1.87B+41.4% | $1.32B+0.9% | $1.31B+15.5% | $1.13B+12.2% | $1.01B-4.4% | ||
| —— | —— | —— | —— | —— | ||
| -$784.8M-197% | -$264.4M+5.5% | -$279.8M— | —— | —— | ||
| —— | —— | —— | $467.7M+3.9% | $450M+50.0% | ||
| $120.9M-6.6% | $129.4M+26.7% | $102.1M+23.2% | $82.9M-1.7% | $84.3M-31.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$411.2M+41.3% | -$700.9M-36.6% | ||
| $72.4M-84.9% | $480M+5,493% | -$8.9M-107% | $124.3M+161% | -$202.2M-1,017% | ||
| $81.1M-0.4% | $81.4M-44.5% | $146.6M-25.7% | $197.2M-9.5% | $217.9M+0.2% | ||
| $9.4M-26.0% | $12.7M-22.1% | $16.3M-18.9% | $20.1M-15.2% | $23.7M-9.5% | ||
| $3.2M-22.0% | $4.1M+5.1% | $3.9M+2.6% | $3.8M+2.7% | $3.7M+2.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $26.8M+18.1% | $22.7M+22.0% | $18.6M+28.3% | $14.5M+39.4% | ||
| $1.05B-3.6% | $1.09B+1.6% | $1.07B-3.6% | $1.11B+12.5% | $989.3M+2.3% | ||
| —— | —— | —— | —— | —— | ||
| $831.3M+11.0% | $748.7M+26.2% | $593.1M+12.2% | $528.7M+7.4% | $492.2M-11.7% | ||
| $831.3M+11.0% | $748.7M+26.2% | $593.1M+12.2% | $528.7M+7.4% | $492.2M-11.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neurocrine Biosciences generate?
- Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
- What is Neurocrine Biosciences's free cash flow?
- After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
- Where does Neurocrine Biosciences's cash flow data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
